Evaluation of metagenomic next‐generation sequencing diagnosis for invasive pulmonary aspergillosis in immunocompromised and immunocompetent patients
Mycoses · 2023
DOI: 10.1111/myc.13557 ↗Kurz gefasst
Fachartikel in der Zeitschrift Mycoses, 2023. Verfasst von Wenyu Zhan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Respiratory Department, Tianjin Medical University General Hospital, Tianjin, China. Hauptthemen laut MEDLINE: Invasive Pulmonary Aspergillosis. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: National Major Science and Technology Projects of China, National Natural Science Foundation of China (82170097 81970083, 81270144, 81570084, and 30800507 to JF), the National Key Technology R D Program, China.
Abstract (Originalsprache)
Background
Invasive pulmonary aspergillosis (IPA) can occur in both immunocompromised and non‐immunocompromised hosts, and early diagnosis of IPA is difficult. Metagenomic next‐generation sequencing (mNGS) is a novel non‐migratory pathogen detection method; however, utilising this method for IPA diagnosis is challenging due to the current lack of a unified clinical interpretation standard following Aspergillus detection using mNGS.
Objectives
To investigate the accuracy of IPA diagnosis by positive bronchoalveolar lavage fluid (BALF) mNGS results in immunocompromised and immunocompetent patients.
Methods
We retrospectively included patients with confirmed pulmonary infections having a BALF mNGS result of Aspergillus reads ≥1. We compared the accuracy of using mNGS for IPA diagnosis in patients with different immune statuses based on the revised EORTC/MSG criteria.
Results
Overall, 62 mNGS Aspergillus ‐positive patients were divided into two groups: with (41) and without IPA (21). In univariate logistic regression analysis, immunocompromised function, fever, halo sign on CT image, and multiple masses or nodules were associated with mNGS Aspergillus ‐positive IPA diagnosis. In multivariate logistic regression analysis, immunocompromised function (OR = 6.68, 95% CI: 1.73–25.87, p = .006) and a halo sign (OR = 7.993, 95% CI: 2.07–30.40, p = .003) were independent risk factors. The concordance rate of IPA diagnosis was significantly higher in immunocompromised patients [82.1% (23/28)] than in non‐immunocompromised patients [52.9% (18/34); p = .016].
Conclusions
For immunocompromised patients, a combination of mNGS testing and lung CT imaging can be used for IPA diagnosis. However, caution is required in IPA diagnosis based on positive mNGS results in non‐immunocompromised patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Respiratory Department, Tianjin Medical University General Hospital, Tianjin, China.
- Department of Geriatrics, The Second Hospital of Tianjin Medical University, Tianjin, China.
ORCID-Profile: Wenyu Zhan
Förderung
- National Major Science and Technology Projects of China
- National Natural Science Foundation of China (82170097 81970083, 81270144, 81570084, and 30800507 to JF)
- the National Key Technology R D Program, China
- Tianjin Key Medical Discipline (Specialty) Construction Project
Zitieren
APA
Zhan, W., Liu, Q., Yang, C., Zhao, Z., Yang, L., Wang, Y., & Feng, J. (2023). Evaluation of metagenomic next‐generation sequencing diagnosis for invasive pulmonary aspergillosis in immunocompromised and immunocompetent patients. Mycoses. https://doi.org/10.1111/myc.13557
Vancouver
Zhan W, Liu Q, Yang C, Zhao Z, Yang L, Wang Y, et al. Evaluation of metagenomic next‐generation sequencing diagnosis for invasive pulmonary aspergillosis in immunocompromised and immunocompetent patients. Mycoses. 2023. doi:10.1111/myc.13557
BibTeX
@article{Zhan2023,
author = {Zhan, Wenyu and Liu, Qingjun and Yang, Changqing and Zhao, Zhan and Yang, Lei and Wang, Yubao and Feng, Jing},
title = {Evaluation of metagenomic next‐generation sequencing diagnosis for invasive pulmonary aspergillosis in immunocompromised and immunocompetent patients},
journal = {Mycoses},
year = {2023},
doi = {10.1111/myc.13557}
}
EUVIMED